Researchers found that naturally-occurring CD7-negative T cells avoid self-destruction and are good effectors in CAR T therapy for T cell blood cancers. Deanna earned their PhD in cellular biology ...

a clinical-stage U.S. biotechnology company developing allogeneic, off-the-shelf cell therapies for the treatment of hematological and solid tumor malignancies, today announced the dosing of the first ...